Lipidemia
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
NewAmsterdam PharmaNARRDEN, Netherlands
2 programs2
obicetrapib 10 mg + ezetimibe 10 mg FDC dailyPhase 31 trial
obicetrapib 10 mg + ezetimibe 10 mg FDC dailyPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
NewAmsterdam Pharmaobicetrapib 10 mg + ezetimibe 10 mg FDC daily
NewAmsterdam Pharmaobicetrapib 10 mg + ezetimibe 10 mg FDC daily
Clinical Trials (2)
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Start: Dec 2025Est. completion: Jun 2028
Phase 3Not Yet Recruiting
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Start: May 2024Est. completion: Mar 2027
Phase 3Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space